 Clinical-stage biotechnology firm Equillium NASDAQ: EQ , which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data regarding itolizumab. A monoclonal antibody, itolizumab aims to provide positive outcomes for patients suffering from lupus nephritis or LN. 